Andon Health Co.Ltd(002432) the limit fell by a large amount at a high level. According to the after hours data, Qianhai securities Shenzhen Branch sold 475 million yuan and one institution sold 138 million yuan.
Andon Health Co.Ltd(002432) in the afternoon, the trading volume of large single seal fell by the limit was nearly 8 billion yuan, up nearly 13 times before
Andon Health Co.Ltd(002432) (002432) rose once after the high opening on the 18th, reaching an intraday high of 88.88 yuan, setting a new record high again, then fell quickly and closed the limit in the afternoon. As of press time, the stock was reported at RMB 74.53, with 110000 orders sealed on the limit board, a turnover of nearly RMB 8 billion, and a turnover rate of more than 20%. Since November 2021, the stock has continued to rise. As of yesterday’s closing, the stock has risen nearly 13 times.
On the 16th, Andon Health Co.Ltd(002432) announced that the company learned in the early morning of January 15, 2022 Beijing time that it was authorized by the U.S. Food and Drug Administration (FDA) to the U.S. subsidiary ihealth labs Inc. The New Coronavirus (SARS-CoV-2) antigen detected by iHealth (POC) (PointOf Care) professional edition Kit (colloidal gold immunochromatography) was used for emergency use authorization (EUA), and the authorization letter from the US Food and Drug Administration (FDA) to iHealth America was received. After obtaining the U.S. emergency use authorization (EUA), the product can be used in the United States and countries / regions that recognize the U.S. fdaeua during the U.S. public health emergency state.
The company said that the product has enriched the company’s covid-19 antigen detection product line through emergency use authorization (EUA), which can contribute to public health and epidemic prevention to a greater extent, provide professional covid-19 virus detection solutions for public health and epidemic prevention, and may bring relevant sales revenue and performance to the company in the future.
On the morning of Andon Health Co.Ltd(002432) 14, it was announced that the U.S. subsidiary and ACC signed the purchase contract on January 13, 2022 local time to sell ihealth kit products. The total amount of contract price tax was $1.275 billion, about 8.1 billion yuan, which has exceeded 50% of the company’s audited main business income in 2020.
Recently, the company also disclosed that as of January 12, the total amount of orders and contracts between its U.S. subsidiary and the Department of health of New York amounted to RMB 1.18 billion, and the contract amount signed with the Executive Office of the federal and Department of health and human services of Massachusetts was about RMB 940 million. The above orders amounted to RMB 2.1 billion, exceeding the total operating revenue of the company in 2020.
The company issued a risk warning again on the 17th, saying that the single month performance of the kit product does not represent the annual performance, and the historical performance of the product does not represent the future performance. The company’s share price is currently at an all-time high, which does not rule out the risk of falling in the future.
At the same time, the company pointed out eight risks in terms of the uncertainty of epidemic development and market competition in the United States, and especially pointed out that the contract and order execution between the U.S. subsidiary and New York, Massachusetts and the U.S. Department of health and human services were affected by local epidemic, the company’s supply chain capacity and other factors, There may be a risk of failure to perform on schedule or in full. The U.S. government can request to stop the execution of the contract and cancel the subsequent procurement without any reason. The Seller shall bear the corresponding risks and possible losses.
In addition, the company also needs to remind investors of the following situations: 1. In its previous announcement, the company mentioned the epidemic prevention related plan issued by the U.S. government, as well as the relevant policies, procurement and distribution plans and conditions of covid-19 antigen household self-test kit products. Investors are reminded that the relevant information and procurement involved in the above contents are not only for the company. Investors are requested not to misunderstand the contents and misinfer the changes it brings to the company’s performance.
2. The sales information disclosed by the company in the previous announcement cannot represent the profit. Because the profit is related to many factors such as raw material cost, product transportation expense, production and manufacturing expense, sales expense, management expense and R & D expense, it is impossible to calculate the profit from the sales amount. Please pay attention to the subsequent announcement of the company for the relevant information of the company’s performance.
3. There are many factors affecting the stock price of the secondary market, and the development of the epidemic in the United States in the future is still uncertain. The sales of kit products are affected by many factors. Investors are invited to pay attention to investment risks and invest rationally.
4. The company previously submitted the proposal on using family self-test box to realize Omicron covid-19 epidemic prevention 1 + 1 to Tianjin epidemic prevention and control headquarters. At present, it is uncertain whether the proposal will be adopted. (source: Securities Times)
